The Critical Role of Comorbidities in Managing Heart Failure with Preserved Ejection Fraction (HFpEF)

The Critical Role of Comorbidities in Managing Heart Failure with Preserved Ejection Fraction (HFpEF)

Saved in:

Bibliographic Details
Main Authors:	Piotr Gajewski, Robert Zymlinski, Jan Biegus
Format:	Article
Language:	English
Published:	Wiley 2025-06-01
Series:	ESC Heart Failure
Online Access:	https://doi.org/10.1002/ehf2.15169
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Alterations of myocardial ketone metabolism in heart failure with preserved ejection fraction (HFpEF)
by: Qiuyu Sun, et al.
Published: (2025-08-01)

Features of heart failure with preserved ejection fraction (HFpEF) in diabetic patients with resistant hypertension
by: M. A. Manukyan, et al.
Published: (2021-11-01)

Heart failure with preserved ejection fraction (HFpEF) pathophysiology study (IDENTIFY-HF): does increased arterial stiffness associate with HFpEF, in addition to ageing and vascular effects of comorbidities? Rationale and design
by: Prithwish Banerjee, et al.
Published: (2019-11-01)

Heart failure with preserved ejection fraction (HFpEF): phenotypes, diagnostic algorithms, and new therapeutic options
by: Arnold Péter Ráduly, et al.
Published: (2025-02-01)

A Retrospective Comparative Study of Sex-Based Risk Variations in Heart Failure With Preserved Ejection Fraction (HFpEF) Versus Heart Failure With Reduced Ejection Fraction (HFrEF)
by: Kristen Yeh, et al.
Published: (2025-08-01)

Microvascular dysfunction across organs in heart failure with preserved ejection fraction: the PROSE-HFpEF case-control study
by: Jerremy Weerts, et al.
Published: (2025-07-01)

A predictive model for heart failure with preserved ejection fraction following acute myocardial infarction: the HFpEF-AMI score
by: Xi Wu, et al.
Published: (2025-07-01)

Study protocol for the PURSUIT-HFpEF study: a Prospective, Multicenter, Observational Study of Patients with Heart Failure with Preserved Ejection Fraction
by: Hiroyasu Iso, et al.
Published: (2020-10-01)

Resistance Exercise in Treating Heart Failure with Preserved Ejection Fraction (HFpEF) and Obesity: Targeting Skeletal Muscle Abnormalities and Ectopic Adipose Depots
by: Daniel J. McDonough
Published: (2025-02-01)

Role and prognostic value of growth differentiation factor 15 in patient of heart failure with preserved ejection fraction: insights from the PURSUIT-HFpEF registry
by: Tetsuhisa Kitamura, et al.
Published: (2025-01-01)

Does HFpEF Exist? A Comment on “The Concept of ‘Heart Failure with Preserved Ejection Fraction’: Time for a Critical Reappraisal” (Rev Cardiovasc Med. 2023;24(7):202)
by: Maria Giulia Bellicini
Published: (2025-07-01)

Phosphorylation of cMyBP-C contributes to the preservation of ejection fraction in the early stages of a mouse model of HFpEF
by: Paola Rosas, et al.
Published: (2025-06-01)

The gut microbiota-inflammation-HFpEF axis: deciphering the role of gut microbiota dysregulation in the pathogenesis and management of HFpEF
by: Shenghua Zhou, et al.
Published: (2025-03-01)

Cardiometabolic Phenotype in HFpEF: Insights from Murine Models
by: Ekaterina Ogurtsova, et al.
Published: (2025-03-01)

Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF
by: Lingyun Luo, et al.
Published: (2025-04-01)

A two‐phase approach to identifying HFpEF in heart failure patients: Risk score evaluation and decision tree development
by: Izabella Uchmanowicz, et al.
Published: (2025-08-01)

Semaglutide: an emerging treatment option for patients with obesity related HFpEF
by: Sanya Ashraf Khaskheli, et al.
Published: (2024-08-01)

Mechanism-based myofilament manipulation to treat diastolic dysfunction in HFpEF
by: Katherine L. Dominic, et al.
Published: (2024-12-01)

V02max Determinants Are Associated With Different Cognitive Outcomes in Women With HFrEF and HFpEF
by: C. Gagnon, et al.
Published: (2025-06-01)

Diagnostic and therapeutic practice for HFpEF across continents and regions: An international survey
by: Inga J. Ingimarsdóttir, et al.
Published: (2025-02-01)

Targeting atrial fibrillation in HFpEF: the emerging role of pulsed field ablation
by: A. S. Parwani, et al.
Published: (2025-07-01)

Prognostic significance of FT3 levels in hypertrophic cardiomyopathy patients with HFpEF
by: Zhen-Yu Yang, et al.
Published: (2025-08-01)

Identification of noval diagnostic biomarker for HFpEF based on proteomics and machine learning
by: Muyashaer Abudurexiti, et al.
Published: (2025-04-01)

Inter‐atrial block as a predictor of adverse outcomes in patients with HFpEF
by: Jerremy Weerts, et al.
Published: (2025-06-01)

The Possible Role of Rosuvastatin Therapy in HFpEF Patients—A Preliminary Report
by: Tomasz Urbanowicz, et al.
Published: (2024-11-01)

The contribution of a short electrocardiographic diastolic interval to diastolic dysfunction and HFpEF
by: A. M. L. N. van Ommen, et al.
Published: (2025-05-01)

Clinical effectiveness and cost-effectiveness of the rehabilitation enablement in chronic heart failure facilitated self-care rehabilitation intervention for people with heart failure with preserved ejection fraction and their caregivers: rationale and protocol for a multicentre randomised controlled trial – REACH-HFpEF trial
by: John G F Cleland, et al.
Published: (2025-05-01)

Propensity score matched cohort study on magnesium supplementation and mortality in critically ill patients with HFpEF
by: Lijun Song, et al.
Published: (2025-01-01)

Decreased Mortality with Beta-Blocker Therapy in HFpEF Patients Associated with Atrial Fibrillation
by: Yanhua Yang, et al.
Published: (2020-01-01)

Sex differences in the association between nutritional status and in‐hospital mortality in HFpEF patients
by: Michał Czapla, et al.
Published: (2025-08-01)

Gender-Specific Differences in Diastolic Dysfunction and HFpEF: Pathophysiology, Diagnosis, and Therapeutic Strategies
by: Francesca Coppi, et al.
Published: (2025-06-01)

Association of serum potassium time in target range with cardiovascular outcomes in patients with HFpEF
by: Yu Liu, et al.
Published: (2025-08-01)

The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction?
by: Francesca Cinti, et al.
Published: (2025-05-01)

The landscape of novel antidiabetic drugs in diabetic HFpEF: relevant mechanisms and clinical implications
by: Xiangling Duan, et al.
Published: (2025-04-01)

Sex‐related pathophysiological mechanisms may be present before symptoms of HFpEF develop
by: B. Wong, et al.
Published: (2025-06-01)

FGF21 protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice
by: Ke Zhang, et al.
Published: (2025-02-01)

Prognosis of early‐stage HFpEF in the community‐dwelling elderly: The Northern Shanghai Study
by: Weilun Meng, et al.
Published: (2025-02-01)

Impact of SGLT2 inhibitors on myocardial fibrosis in diabetic HFpEF: a longitudinal study
by: Arif Albulushi, et al.
Published: (2025-07-01)

Circulating mediators linking cardiometabolic diseases to HFpEF: a mediation Mendelian randomization analysis
by: Mingzhi Lin, et al.
Published: (2025-05-01)

Real world experience in effect of torsemide vs. furosemide after discharge in patients with HFpEF
by: Xiao Li, et al.
Published: (2025-02-01)